Pharos iBio
파로스아이바이오 · 388870
Health Care Biotechnology · KOSDAQ
Market cap US$56.8M (₩78.5B)
Overview
Pharos iBio is a drug-discovery company focused on developing new medicines for rare and hard-to-treat diseases, particularly cancers.
It sits at the research and early clinical stage of the pharmaceutical supply chain, advancing drug candidates toward regulatory approval rather than supplying commercial products. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company's core asset is its proprietary AI-driven drug-discovery platform, called Chemiverse, which integrates large compound databases with multi-omics analysis to identify and optimize small-molecule drug candidates.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$0
- FY2024N/A
- FY2025N/A
Operating profit
- FY2023−US$7.3M
- FY2024−US$9.1M
- FY2025−US$8.3M
Net income
- FY2023−US$6.4M
- FY2024−US$7.7M
- FY2025−US$7.8M
Key ratios (FY2025)
Why it matters
Its lead drug candidate, Lasmotinib, has received orphan-drug designation from the US FDA, the Korean MFDS, and the European EMA, a status that can confer priority review and post-approval market exclusivity in those jurisdictions.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?